Recent statements by Dr. Robert Malone, a member of the CDC’s Advisory Committee on Immunization Practices (ACIP), have raised serious questions about the vote to recommend a new antibody called clesrovimab for infants, aimed at preventing respiratory syncytial virus (RSV). Dr. Malone argues that critical data was missing from presentations that influenced the committee’s decision.
• Dr. Malone claimed that the vote was informed by “manipulated data analyses” during an ACIP meeting held on June 25, 2025.
• Clesrovimab is intended for infants to help prevent RSV, a virus that can lead to severe health issues and is a major cause of infant hospitalizations.
• At the meeting, CDC epidemiologist Adam MacNeil presented data indicating no increased risk for seizures in infants who received nirsevimab, the only existing antibody at the time.
• Two members voted against recommending clesrovimab, advocating for more caution regarding its safety.
• An independent analysis by journalist Maryanne Demasi suggested that infants receiving nirsevimab were four times more likely to experience seizures, which contradicted earlier claims.
• Malone expressed regret about his initial support for the antibody, stating that he no longer trusts CDC data due to the new information and lack of transparency.
• Dr. Retsef Levi, another ACIP member who opposed the recommendation, highlighted the need for greater transparency and discussion of safety concerns.
• The CDC, along with the manufacturers Merck and AstraZeneca, did not respond to inquiries about these findings.
• Dr. Jake Scott, a clinical professor, disagreed with pooling data from different infant age groups for safety assessments, saying it confuses effects from the antibody and vaccines.
The debate surrounding the safety of the RSV antibody clesrovimab has intensified due to new findings and concerns over data transparency. Dr. Malone’s assertions have called into question the integrity of the information presented to the ACIP, highlighting the necessity for careful evaluation of vaccine and antibody safety before widespread use.
No comments:
Post a Comment